Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

89bio (NASDAQ:ETNB – Get Free Report)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

These are some of the best-performing stocks in the health care sector over the past month Nathan Reiff has been writing expert articles and news about financial topics such as investing and ...

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

"One and one please love," a regular said, leaning on the counter at a pie and mash shop in London's East End. In seconds, one piping-hot beef pie appeared with a single scoop of mashed potatoes ...